Phase 3 MS Clinical Trials

49 active trials · 21 recruiting

49 active phase 3 multiple sclerosis trials are listed here, 21 currently recruiting, sourced from ClinicalTrials.gov.

Phase 3 trials are the large, usually randomised studies that compare a treatment against a placebo or an existing therapy in hundreds or thousands of people. Regulators rely on them for approval decisions.

Active Phase 3 MS trials

RecruitingPhase 3

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

Ublituximab · Ublituximab

360 participantsDetails ›

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Remibrutinib (blinded) · Placebo

10 states1275 participantsDetails ›

RecruitingPhase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Frexalimab

6 states160 participantsDetails ›

RecruitingPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Sponsor: Zenas BioPharma (USA), LLC

Orelabrutinib · Placebo

1 state990 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

RecruitingPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Sponsor: Sandoz

CYB704 · Ocrevus-EU

1 state175 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingPhase 3

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Sponsor: Hoffmann-La Roche

Ocrelizumab

500 participantsDetails ›

RecruitingPhase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Sponsor: Celgene

Ozanimod · Fingolimod

9 states194 participantsDetails ›

RecruitingPhase 3

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Sponsor: Rennes University Hospital

Perfusion of treatment Rituximab · Perfusion of treatment Ocrelizumab

386 participantsDetails ›

RecruitingPhase 3

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Ocrelizumab Injection [Ocrevus] · Ocrelizumab Injection [Ocrevus]

244 participantsDetails ›

RecruitingPhase 3

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Sponsor: Biocad

BCD-281 · Ocrelizumab

292 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

RecruitingPhase 3

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Sponsor: Zenas BioPharma (USA), LLC

Orelabrutinib · Placebo

2 states705 participantsDetails ›

RecruitingPhase 3

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

Sponsor: Amsterdam UMC, location VUmc

Clemastine Fumarate · Placebo

80 participantsDetails ›

RecruitingPhase 3

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Sponsor: Celltrion

CT-P53 · US-Ocrevus

512 participantsDetails ›

RecruitingPhase 2

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Sponsor: Institute of Psychiatry and Neurology, Warsaw

Cladribine Subcutaneous Injection · 0.9% Chloride Injection Sodium

188 participantsDetails ›

RecruitingPhase 3

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Sponsor: Amsterdam UMC, location VUmc

Rituximab

200 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)

Sponsor: Rennes University Hospital

DMT withdrawal · DMT continuation

250 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Fingolimod · Ofatumumab

6 states129 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

13 states751 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Sponsor: TG Therapeutics, Inc.

Ublituximab

14 states1100 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 tablets · Placebo matching IMU-838 tablets

1 state1100 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab · Placebo

5 states1013 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 tablets · Placebo matching IMU-838 tablets

4 states1121 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Interferon beta-1a · Fingolimod

8 states240 participantsDetails ›

Closed to new patientsPhase 3

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Sponsor: AB Science

Placebo · Masitinib (4.5)

800 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Sponsor: Biogen

BIIB017 (peginterferon beta-1a) · Interferon beta type 1a

3 states152 participantsDetails ›

Closed to new patientsPhase 2

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Sponsor: Queen Mary University of London

Cladribine (MAVENCLAD®) · Placebo

204 participantsDetails ›

Closed to new patientsPhase 3

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Sponsor: Rigshospitalet, Denmark

Rituximab · Ocrelizumab

600 participantsDetails ›

Closed to new patientsPhase 3

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Sponsor: Haukeland University Hospital

Rituximab · Ocrelizumab

214 participantsDetails ›

Closed to new patientsPhase 3

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Sponsor: Haukeland University Hospital

Cyclophosphamide and ATG · Alemtuzumab

100 participantsDetails ›

Closed to new patientsPhase 2

Adderall XR and Cognitive Impairment in MS

Sponsor: Sarah Morrow

Adderall XR

180 participantsDetails ›

Closed to new patientsPhase 3

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

Sponsor: Centre Hospitalier Universitaire de Nice

Ocrelizumab

72 participantsDetails ›

MS trials by phase

Phase 2 (60)Phase 1 (43)Phase 4 (19)

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.